Skip to content 
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In addition, the company is developing LPCN 2201, an oral brexanolone formulation that has completed a Phase 1 trial for major depressive disorders; LPCN 2203, an oral candidate that has completed a Phase 1 trial for management of essential tremor; and LPCN 2101, a neuroactive steroids (NAS) candidate that has completed a Phase 1 trial for drug-resistant epilepsy and women with epilepsy. The company's products focus on neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation in the United States. It has a collaboration with Verity Pharmaceuticals, Inc. to develop and commercialize TLANDO; and TLANDO XR (LPCN 1111), a once-daily oral product candidate that has completed a Phase 2 trial for testosterone replacement therapy. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah. more
| Time Frame | LPCN | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 8.56% | 1.26% | -0.8% |
| 1-Month Return | -9.62% | -7.52% | -5.34% |
| 3-Month Return | -0.5% | -5.29% | -4.72% |
| 6-Month Return | 180.35% | 5.35% | -2.42% |
| 1-Year Return | 151.26% | 0.41% | 16.28% |
| 3-Year Return | 47.75% | 13.25% | 58.89% |
| 5-Year Return | -68.87% | 25.59% | 64.03% |
| 10-Year Return | -95.37% | 116.3% | 216.9% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 16.14M | 500.00K | (2.85M) | 11.20M | 1.98M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":3.1,"profit":true},{"date":"2023-12-31","value":-17.66,"profit":false},{"date":"2024-12-31","value":69.38,"profit":true},{"date":"2025-12-31","value":12.25,"profit":true}] |
| Cost of Revenue | 7.67M | 8.56M | 10.18M | 41.11K | 8.58M | [{"date":"2021-12-31","value":75.34,"profit":true},{"date":"2022-12-31","value":84.1,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":0.4,"profit":true},{"date":"2025-12-31","value":84.36,"profit":true}] |
| Gross Profit | 8.48M | (8.06M) | (13.03M) | 11.20M | (6.61M) | [{"date":"2021-12-31","value":75.68,"profit":true},{"date":"2022-12-31","value":-71.95,"profit":false},{"date":"2023-12-31","value":-116.32,"profit":false},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":-59,"profit":false}] |
| Gross Margin | 52.51% | (1611.38%) | 456.92% | 100.00% | (334.26%) | [{"date":"2021-12-31","value":11.49,"profit":true},{"date":"2022-12-31","value":-352.66,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":21.89,"profit":true},{"date":"2025-12-31","value":-73.15,"profit":false}] |
| Operating Expenses | 5.33M | 4.06M | 4.90M | 12.35M | 3.76M | [{"date":"2021-12-31","value":43.14,"profit":true},{"date":"2022-12-31","value":32.89,"profit":true},{"date":"2023-12-31","value":39.71,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":30.47,"profit":true}] |
| Operating Income | 3.15M | (12.12M) | (17.93M) | (1.16M) | (10.37M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-385.29,"profit":false},{"date":"2023-12-31","value":-570.05,"profit":false},{"date":"2024-12-31","value":-36.72,"profit":false},{"date":"2025-12-31","value":-329.72,"profit":false}] |
| Total Non-Operating Income/Expense | (3.92M) | 1.91M | 2.94M | 2.31M | 1.49M | [{"date":"2021-12-31","value":-132.98,"profit":false},{"date":"2022-12-31","value":64.76,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":78.49,"profit":true},{"date":"2025-12-31","value":50.54,"profit":true}] |
| Pre-Tax Income | (634.20K) | (10.76M) | (16.35M) | 9.03K | (9.63M) | [{"date":"2021-12-31","value":-7020.91,"profit":false},{"date":"2022-12-31","value":-119096.15,"profit":false},{"date":"2023-12-31","value":-181017.68,"profit":false},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":-106579.26,"profit":false}] |
| Income Taxes | 200.00 | 681.00 | 755.00 | 681.00 | 200.00 | [{"date":"2021-12-31","value":26.49,"profit":true},{"date":"2022-12-31","value":90.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":90.2,"profit":true},{"date":"2025-12-31","value":26.49,"profit":true}] |
| Income After Taxes | (634.40K) | (10.76M) | (16.35M) | 8.35K | (9.63M) | [{"date":"2021-12-31","value":-7595.77,"profit":false},{"date":"2022-12-31","value":-128815.09,"profit":false},{"date":"2023-12-31","value":-195786.42,"profit":false},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":-115271.85,"profit":false}] |
| Income From Continuous Operations | (634.40K) | (10.76M) | (16.30M) | 8.35K | (9.63M) | [{"date":"2021-12-31","value":-7595.77,"profit":false},{"date":"2022-12-31","value":-128815.09,"profit":false},{"date":"2023-12-31","value":-195159.75,"profit":false},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":-115271.85,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | (634.40K) | (10.76M) | (16.35M) | 8.35K | (9.63M) | [{"date":"2021-12-31","value":-7595.77,"profit":false},{"date":"2022-12-31","value":-128815.09,"profit":false},{"date":"2023-12-31","value":-195786.42,"profit":false},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":-115271.85,"profit":false}] |
| EPS (Diluted) | 0.05 | (0.13) | (3.05) | 0.01 | (1.77) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-260,"profit":false},{"date":"2023-12-31","value":-6100,"profit":false},{"date":"2024-12-31","value":20,"profit":true},{"date":"2025-12-31","value":-3540,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| LPCN | |
|---|---|
| Cash Ratio | 5.91 |
| Current Ratio | 6.68 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| LPCN | |
|---|---|
| ROA (LTM) | -32.81% |
| ROE (LTM) | -54.28% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| LPCN | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.15 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.85 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| LPCN | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 27.99 |
| P/B | 3.49 |
| Price/FCF | NM |
| EV/R | 18.00 |
| EV/Ebitda | 0.65 |
| PEG | NM |
Lipocine Inc (LPCN) share price today is $8.559
Yes, Indians can buy shares of Lipocine Inc (LPCN) on Vested. To buy
Yes, you can purchase fractional shares of Lipocine Inc (LPCN) via the Vested app. You can start investing in Lipocine Inc (LPCN) with a minimum investment of $1.
You can invest in shares of Lipocine Inc (LPCN) via Vested in three simple steps:
The 52-week high price of Lipocine Inc (LPCN) is $12.37. The 52-week low price of Lipocine Inc (LPCN) is $2.52.
The price-to-earnings (P/E) ratio of Lipocine Inc (LPCN) is
The price-to-book (P/B) ratio of Lipocine Inc (LPCN) is 3.49
The dividend yield of Lipocine Inc (LPCN) is 0.00%
The market capitalization of Lipocine Inc (LPCN) is $58.32M
The stock symbol (or ticker) of Lipocine Inc is LPCN
Consider the share price of Lipocine Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Lipocine Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Lipocine Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Lipocine Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Lipocine Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Lipocine Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
